 "From Mankind to Alkem, top five pharma firms hit by the ban on FDCs")
The health ministry last week banned 328 fixed dose combination drugs (FDCs) following recommendations of the drug technical advisory board. These drugs were found to be irrational and without therapeutic justification. Also, manufacture and sale of six other FDCs has been regulated. Fifteen FDCs have been exempted from the ban in accordance with the order of the SC.
Here’s the lowdown on its impact on pharma firms:
Here’s the lowdown on its impact on pharma firms:
Annual domestic pharmaceutical market size: Rs 1.24 trillion
Market size of 328 banned FDCs: Rs 10.40 billion which is 0.8% of the total
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%